Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Free Cash Flow (2020 - 2025)

Rapid Micro Biosystems' Free Cash Flow history spans 6 years, with the latest figure at -$8.4 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 11.16% year-over-year to -$8.4 million; the TTM value through Sep 2025 reached -$38.1 million, up 13.49%, while the annual FY2024 figure was -$44.5 million, 2.33% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$8.4 million at Rapid Micro Biosystems, up from -$10.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$6.3 million in Q4 2022 and bottomed at -$19.8 million in Q3 2021.
  • The 5-year median for Free Cash Flow is -$10.6 million (2024), against an average of -$12.3 million.
  • The largest annual shift saw Free Cash Flow plummeted 132.48% in 2021 before it skyrocketed 53.75% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$13.6 million in 2021, then surged by 53.75% to -$6.3 million in 2022, then plummeted by 54.86% to -$9.7 million in 2023, then dropped by 4.66% to -$10.2 million in 2024, then increased by 17.27% to -$8.4 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Free Cash Flow are -$8.4 million (Q3 2025), -$10.1 million (Q2 2025), and -$9.4 million (Q1 2025).